Codrituzumab
Term · Oncology and biomedicine · MLC-T-ONC-012694
A humanized monoclonal antibody directed against the cell surface oncofetal protein glypican-3 (GPC3) with potential antineoplastic activity. Anti-GPC3 monoclonal antibody GC33 binds to GPC3 and triggers a host immune response against GPC3-expressing tumor cells, which may result in tumor cell death. GPC3, a heparin sulfate proteoglycan, is frequently upregulated in hepatocellular carcinoma and mesoderm-derived organs such as the liver, lungs, and kidney.
| Identifier | MLC-T-ONC-012694 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-glypican 3 monoclonal antibody GC33 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012694",
"term": "Codrituzumab",
"field": "Oncology and biomedicine",
"definition": "A humanized monoclonal antibody directed against the cell surface oncofetal protein glypican-3 (GPC3) with potential antineoplastic activity. Anti-GPC3 monoclonal antibody GC33 binds to GPC3 and triggers a host immune response against GPC3-expressing tumor cells, which may result in tumor cell death. GPC3, a heparin sulfate proteoglycan, is frequently upregulated in hepatocellular carcinoma and mesoderm-derived organs such as the liver, lungs, and kidney.",
"synonyms": [
"anti-glypican 3 monoclonal antibody GC33"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/codrituzumab/"
}
Record 5,060 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.